ASTRAZEN - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.2
✅ Positive
The recent CDSCO approvals for both breast cancer and bladder cancer treatments indicate positive developments for AstraZeneca Pharma India, potentially boosting future revenue streams. Furthermore, increased DII holding suggests growing investor confidence in the company’s prospects.
⚠️ Limitation
Despite favorable news regarding approvals, the stock's high P/E ratio (106) and PEG Ratio (7.16) suggest potential overvaluation and vulnerability to market corrections. The negative quarter profit variance (-26.6%) also raises concerns about short-term earnings performance.
📉 Company Negative News
AstraZeneca Pharma India received CDSCO nods for importing and distributing breast cancer and bladder cancer drugs, causing a 3% jump in its shares. This approval directly addresses specific therapeutic areas of interest, signaling potential growth opportunities.
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical sector is currently experiencing moderate growth driven by increasing healthcare expenditure and advancements in drug research. However, competitive pressures and regulatory scrutiny remain significant challenges for companies like AstraZeneca, especially given the cyclical nature of the industry.
🧾 Conclusion
Based on technical analysis, the stock appears to be consolidating around the 8,142 ₹ level with support at approximately 7,552 ₹ and resistance near 9,850 ₹. An optimal entry zone could be between 7,800 - 8,000 ₹, utilizing a stop-loss order below 7,552₹. Overall, the stock presents a cautiously optimistic outlook pending further evidence of sustained earnings growth.